Delivery Order SPE2DB22D2206-SPE2DB25FJK98
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Zoladex 10.8 mg implant syringes under a firm fixed-price contract with a ceiling value of $7,564.32. The contract is scheduled for ultimate completion by August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Zoladex 10.8 mg implant syringes, with a ceiling value of $3,719.00 and ultimate completion date of October 1, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Zoladex 10.8 mg implant syringes, with a contract ceiling value of $37,190. This is a firm fixed-price delivery order with an ultimate completion date of August 11, 2025, and represents a non-set-aside competitive award. The delivery will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a major...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $9,297.50 on August 12, 2025, for the supply of Zoladex 10.8 mg implant syringes, with a completion date of September 3, 2025. This non-set-aside, competitively awarded contract carries firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location...
- On August 14, 2025, the Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for Zoladex 10.8 mg implant syringes, with a ceiling value of $5,578.50. This firm fixed-price delivery order represents a non-competitive set-aside procurement and is scheduled for completion by September 5, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Zoladex is a hormone...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 21, 2025, for the supply of Zoladex 10.8 mg implant syringes, with a ceiling value of $1,859.50 and a firm fixed price. This competitively awarded, non-set-aside contract is classified as a delivery order and is scheduled for completion by June 12, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, reflecting the company's role as a major pharmaceutical...
- The Defense Logistics Agency awarded a $5,578.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zoladex 10.8 mg implant syringes. The contract was competitively awarded without set-aside designation and carries an ultimate completion date of September 3, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania will serve as the place of performance for this pharmaceutical supply delivery. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Zoladex 10.8 mg implant syringes, with a ceiling value of $2,789.25. This is a firm fixed-price delivery order with an ultimate completion date of October 1, 2025, and represents a non-set-aside competitive award. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $16,735.50 for Zoladex 10.8 mg implant syringes on August 8, 2025, with completion targeted for August 29, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Zoladex 10.8 mg implant syringes, with a ceiling value of $22,314. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of October 7, 2025. The contract will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJK98Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zoladex 10.8 mg implant syringes, with a ceiling value of $11,157. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 5, 2025. This delivery order is a child contract issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999, which runs through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The company's primary IDC vehicle with DLA enables it to supply a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. Zoladex, a hormone treatment medication commonly used in oncology and endocrinology applications, represents part of the specialized pharmaceutical products the company routinely delivers through its federal contract portfolio. The rapid completion timeline indicates this delivery order fulfills an urgent medical supply requirement within the federal healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.2k | 8/14/25 |